Friday, 21 October 2016

Uterine Leiomyoma Global Market Segmentation and Major Players Analysis 2022

The report provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and features dormant and discontinued projects.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

- The report provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Uterine Fibroids)
- The report reviews pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Uterine Leiomyoma (Uterine Fibroids) therapeutics and enlists all their major and minor projects
- The report assesses Uterine Leiomyoma (Uterine Fibroids) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids)

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Uterine Leiomyoma (Uterine Fibroids)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Uterine Leiomyoma (Uterine Fibroids) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Uterine Leiomyoma (Uterine Fibroids) Overview 8
Therapeutics Development 9
Pipeline Products for Uterine Leiomyoma (Uterine Fibroids) - Overview 9
Pipeline Products for Uterine Leiomyoma (Uterine Fibroids) - Comparative Analysis 10
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics under Development by Companies 11
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics under Investigation by Universities/Institutes 12
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Uterine Leiomyoma (Uterine Fibroids) - Products under Development by Companies 16
Uterine Leiomyoma (Uterine Fibroids) - Products under Investigation by Universities/Institutes 17
Uterine Leiomyoma (Uterine Fibroids) - Companies Involved in Therapeutics Development 18
AbbVie Inc. 18
Addex Therapeutics Ltd 19
Bayer AG 20
BioSpecifics Technologies Corp. 21
Dongkook Pharmaceutical Co., Ltd. 22
Euroscreen S.A. 23
Kissei Pharmaceutical Co., Ltd. 24
Laboratoire HRA Pharma 25
Repros Therapeutics Inc. 26
Takeda Pharmaceutical Company Limited 27
Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31

Contact Info:
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)                                                   

Get in touch:

No comments:

Post a Comment